Additional Proxy Soliciting Materials (definitive) (defa14a)
December 30 2020 - 6:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
|
☐
|
Preliminary
Proxy Statement
|
|
☐
|
Confidential,
For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive
Proxy Statement
|
|
☒
|
Definitive
Additional Materials
|
|
☐
|
Soliciting
Material Under Rule 14a-12
|
Enzo
Biochem, Inc.
(Name
of Registrant as Specified in Its Charter)
(Name
of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
☒
|
No
fee required
|
|
|
☐
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
☐
|
Fee
paid previously with preliminary materials.
|
|
|
☐
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date
of its filing.
|
|
(1)
|
Amount
previously paid:
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
ENZO
BIOCHEM, INC.
527
Madison Avenue
New York, New York 10022
2020
ANNUAL MEETING OF SHAREHOLDERS
To
be held on January 4, 2021
Please
vote ENZO’s proxy so your vote can be counted
PLEASE
VOTE FOR:
|
1.
|
the
election of (i) Elazar Rabbani, Ph.D. and Ian Walters, M.D. to the Company’s Board of Directors (the “Board”)
as Class III Directors, to hold office for a term of three (3) years or until their successors have been duly elected and
qualified, and (ii) Mary Tagliaferri, M.D. to the Board as a Class II Director, to hold office for a term of two (2) years
or until her successor has been duly elected and qualified;
|
|
|
|
|
2.
|
the
approval, by a nonbinding advisory vote, of the compensation of the Company’s Named Executive Officers;
|
|
|
|
|
3.
|
the
ratification of the Company’s appointment of EisnerAmper LLP to serve as the Company’s independent registered
public accounting firm for the Company’s fiscal year ending July 31, 2021; and
|
|
|
|
|
4.
|
the
approval of the amendment and restatement of the Company’s Amended and Restated 2011 Incentive Plan, including an increase
in the number of shares of common stock authorized for grant under such plan.
|
While we strongly
encourage you to vote your shares prior to the virtual Annual Meeting, shareholders may also vote during the meeting.
Virtual-Only Meeting to be Held
As previously disclosed, as a result of the coronavirus (COVID-19)
outbreak, the Annual Meeting will be a completely virtual meeting. There will be no physical meeting location. The Annual Meeting
will be conducted via live webcast. Shareholders will have the same rights and opportunities to participate in the virtual Annual
Meeting as they would at an in-person meeting.
Instructions for the Virtual Annual Meeting
As described in the Proxy Statement, to attend the virtual Annual
Meeting, visit www.virtualshareholdermeeting.com/ENZ2020 and enter your 16-digit control number. If you were a shareholder of record
of the Company’s common stock at the close of business on November 23, 2020 (the “Record Date”) your 16-digit
control number can be found on your proxy card. If you were a beneficial owner of the Company’s common stock at the close
of business on the Record Date (i.e., your shares are held by your broker in “street name”), your16-digit control number
can be found on the notice and instructions received from your broker or other nominee.
Once logged in, you will be able to vote your shares by clicking
the “Vote Here!” button.
Shareholders may also submit written questions via the virtual
platform. Questions pertinent to meeting matters will be answered during the question and answer portion of the virtual Annual
Meeting, subject to a time limit prescribed by the Rules of Conduct that will be posted to the virtual Annual Meeting platform
on the day of the meeting. The Rules of Conduct will also provide additional information about the relevancy of questions to meeting
matters.
The virtual Annual Meeting platform is fully supported across
browsers (Internet Explorer, Firefox, Chrome, and Safari) and devices (desktops, laptops, tablets and cell phones) running the
most updated version of applicable software and plugins. Participants should ensure that they have a strong WiFi connection from
wherever they intend to participate in the virtual Annual Meeting.
If you encounter any difficulties accessing the virtual Annual
Meeting during the check-in or meeting time, you should call the technical support number that will be posted on the virtual shareholder
meeting login page.
The meeting will start at 9:00 a.m., EST on January 4, 2021.
We encourage you to access the virtual Annual Meeting prior to the start time to familiarize yourself with the virtual platform
and ensure you can hear the streaming audio. Online access will be available starting at 8:30 a.m., EST on January 4, 2021.
If you have any questions about the procedures for admission
to the Annual Meeting, please contact Investor Relations at (212) 583-0100.
Company shareholders who have questions about matters to be
voted on at the 2020 Annual Meeting or who desire additional copies of the Proxy Statement or additional proxy or voting instruction
cards should contact:
Enzo Biochem, Inc.
527 Madison Avenue
New York, New York 10022
(212) 583-0100
Attn.: Investor Relations
or
Kingsdale Advisors
(888) 518-1554 (toll-free
in North America)
(416) 867-2272 (outside
of North America)
e-mail: contactus@kingsdaleadvisors.com
IMPORTANT NOTICE REGARDING AVAILABILITY
OF PROXY MATERIALS
The Proxy Statement filed November 23, 2020, the Proxy Supplement
filed December 15, 2020, the form of proxy card, our 2020 Annual Report to Shareholders and our Annual Report on Form 10-K for
our fiscal year ended July 31, 2020, are available to you on our website at www.enzo.com. Shareholders may also obtain a
copy of these materials by writing to Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022, Attention: Barry W. Weiner,
President. Upon payment of a reasonable fee, shareholders may also obtain a copy of the exhibits to our Annual Report on Form 10-K
for our fiscal year ended July 31, 2020.
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024